Back to search
FDAFDA · Food and drugs·Recall number D-0264-2022

Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg), packaged in cartons containing 3 wallets of 28 Tablets each, Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United Stated, Manufactured by: Lupin Limited, Pithampur, (M.P.) - 454775, India, 244896, The individual wallet NDC 68180-904-11 and the carton NDC 68180-904-13.

Published December 8, 2021 · Recall initiated: November 19, 2021

Summary

FDA records drug Class III recall D-0264-2022, published December 8, 2021 and initiated November 19, 2021. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 4113 cartons; Lot: Lot #: L000784 and L000785, Exp. Date May 2022. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
nationwide within the United States
Lot
Lot #: L000784 and L000785, Exp. Date May 2022
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg), packaged in cartons containing 3 wallets of 28 Tablets each, Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United Stated, Manufactured by: Lupin Limited, Pithampur, (M.P.) - 454775, India, 244896, The individual wallet NDC 68180-904-11 and the carton NDC 68180-904-13. recalled?

Yes. FDA published recall D-0264-2022 on December 8, 2021. Reported hazard: Subpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · Letter